ATRA — Atara Biotherapeutics Cashflow Statement
0.000.00%
Last trade - 00:00
- $71.08m
- $2.81m
- $63.57m
2018 December 31st | 2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | -231 | -291 | -307 | -340 | -228 |
Depreciation | |||||
Non-Cash Items | 32.2 | 52.4 | 53.8 | 57.7 | 13.7 |
Unusual Items | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | 15 | -4.15 | 63.7 | 52.6 | -61.5 |
Change in Accounts Receivable | |||||
Change in Inventories | |||||
Change in Prepaid Expenses | |||||
Change in Other Assets | |||||
Change in Accounts Payable | |||||
Change in Accrued Expenses | |||||
Change in Other Liabilities | |||||
Cash from Operating Activities | -180 | -236 | -181 | -221 | -270 |
Capital Expenditures | -35.9 | -5.73 | -4.51 | -10.6 | -4.19 |
Purchase of Fixed Assets | |||||
Other Investing Cash Flow Items | -160 | 66.2 | -116 | 32.8 | 207 |
Sale of Fixed Assets | |||||
Sale/Maturity of Investment | |||||
Purchase of Investments | |||||
Cash from Investing Activities | -196 | 60.5 | -121 | 22.3 | 203 |
Financing Cash Flow Items | 17.2 | 0.655 | 4.99 | 5.5 | 31.7 |
Other Financing Cash Flow | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | 358 | 189 | 428 | 104 | 53.1 |
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | -18.5 | 13.6 | 126 | -94.3 | -14.4 |